Therapeutic effect of dihydroartemisinin on Alzheimer’s disease model mice with senile macular degeneration

European journal of medical research, Год журнала: 2025, Номер 30(1)

Опубликована: Фев. 5, 2025

This study focuses on the preventive and therapeutic effects of Dihydroartemisinin (DHA) Alzheimer's disease (AD) model mice DHA donepezil amyloid β-protein deposition autophagy in nerve cells. Six related targets were selected for molecular docking with to predict affinity between target. The AD mouse was established treated DHA, respectively. Morris water maze used detect spatial learning memory ability mice. Hematoxylin eosin (he) staining observe structural changes cerebral cortical neurons retina, transmission electron microscope mitochondria synapses. Immunohistochemistry (IHC) immunofluorescence beta protein. Western blot expression apoptosis proteins brain tissue each group. results showed that active compounds had good binding activity energy Aβ, Bcl-2, ATG5, LC3, Caspase3, LAMP1 is −5.7, −7.0, −5.8, −7.2, −6.9 kcal/mol. test compared wild type (WT) group, group (5× FAD) significantly decreased, search time (27.62 ± 6.51 s vs. 282.80 17.15 s) average path (106.30 29.65 cm 993.20 135.80 cm) prolonged. application shortened exploration (donepezil: 116.10 10.58 s, 529.40 106.00 cm; DHA: 99.71 14.22 373.30 60.97 cm). find platform treatment shorter than (P < 0.05). HE arrangement cells 5× FAD disordered, IHC obvious. could improve damage cortex structure reduce extracellular Transmission microscopy mitochondrial vacuolation synaptic edema. above effect better donepezil. Compared conventional feeding B-cell lymphoma-2 (BCL2) anti-thymocyte globulin (ATG) down regulated expressions BCL2 ATG increased after combined protein, through promoting can mice, β-amyloid then superior monotherapy.

Язык: Английский

---

Beneficial effects of anticholinesterases: Reducing the anticholinergic load, the missing link of the story?

L Encéphale, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---

Association of outer retinal and choroidal alterations with neuroimaging and clinical features in posterior cortical atrophy

Alzheimer s Research & Therapy, Год журнала: 2024, Номер 16(1)

Опубликована: Авг. 19, 2024

Posterior cortical atrophy (PCA) is a rare condition characterized by early-onset and progressive visual impairment. Individuals with PCA have relatively dementia, posing certain needs for early detection. Hence, this study aimed to investigate the association of alterations in outer retinal choroidal structure microvasculature neuroimaging clinical features possible effects apolipoprotein E(APOE) ε4 allele on participants PCA, detect potential ocular biomarkers screening.

Язык: Английский

---

Hallmarks of aging in age-related macular degeneration and age-related neurological disorders: novel insights into common mechanisms and clinical relevance

Eye, Год журнала: 2024, Номер unknown

Опубликована: Сен. 17, 2024

Язык: Английский

---

Effects and mechanisms of APP and its cleavage product Aβ in the comorbidity of sarcopenia and Alzheimer’s disease

Frontiers in Aging Neuroscience, Год журнала: 2024, Номер 16

Опубликована: Ноя. 25, 2024

Sarcopenia and AD are both classic degenerative diseases, there is growing epidemiological evidence of their comorbidity with aging; however, the mechanisms underlying biology commonality have not yet been thoroughly investigated. APP a membrane protein that expressed in tissues only nervous system but also NMJ muscle. Deposition its proteolytic cleavage product, Aβ, has described as central component pathogenesis. Recent studies shown excessive accumulation aberrant expression muscle lead to pathological lesions, pathogenic mechanism by which products act skeletal less well understood. By summarizing analyzing literature concerning role, pathogenicity muscles, we aimed explore intrinsic myocerebral comorbidities provide new perspectives theoretical foundations for prevention treatment sarcopenia comorbidities.

Язык: Английский

---

Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration

JAMA Network Open, Год журнала: 2024, Номер 7(10), С. e2441166 - e2441166

Опубликована: Окт. 24, 2024

Importance Age-related macular degeneration (AMD) is the leading cause of blindness among people aged 50 years or older worldwide. There a need for new strategies prevention and treatment AMD. some limited evidence to suggest possibility protective association dementia medications with development types AMD, but weak. Objective To investigate whether memantine donepezil are associated risk developing Design, Setting, Participants Three population-based cohort studies were performed using data from Clinical Practice Research Datalink GOLD Aurum databases May 15, 2002, June 21, 2022. included individuals (vascular dementia, nonvascular Alzheimer disease) 40 older. Statistical analysis was carried out between February November 2023. Exposures medications. Cohort 1 compared patients prescribed those rivastigmine galantamine new-user design. 2 donepezil, rivastigmine, prevalent In sensitivity analysis, 3 only. Main Outcomes Measures New diagnosis Results 132 846 (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean body mass index [BMI], 25.5 [4.6]) in 1, 159 419 81.2 59.7% 25.6 [4.7]) 2, 92 328 80.9 [7.7] 58.5% [4.7]). The adjusted hazard ratio (HR) (cohort 1) 0.95 (95% CI, 0.67-1.35). HR 2) 1.03 0.83-1.27). vs only 3) 1.24 0.83-1.86). Conclusions Relevance This study found no significant associations other Further research recommended examine any possible pathophysiological action against

Язык: Английский

---

Acetylcholinesterase Inhibitors, AMD, and Alzheimer Disease—Reply

JAMA Ophthalmology, Год журнала: 2024, Номер 142(7), С. 684 - 684

Опубликована: Май 9, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Язык: Английский

---

Acetylcholinesterase Inhibitors, AMD, and Alzheimer Disease

JAMA Ophthalmology, Год журнала: 2024, Номер 142(7), С. 683 - 683

Опубликована: Май 9, 2024

Язык: Английский

---

Facilitating Drug Repurposing—Using Databases for Drug Discovery in AMD

JAMA Ophthalmology, Год журнала: 2024, Номер 142(8), С. 759 - 759

Опубликована: Авг. 1, 2024

Язык: Английский

---

Dementia Drugs and Age-Related Macular Degeneration

JAMA Network Open, Год журнала: 2024, Номер 7(10), С. e2441172 - e2441172

Опубликована: Окт. 24, 2024

Jingya Wang, PhD; Christina Antza, Wen Hwa Lee, Jesse Coker, Pearse A. Keane, MD; Alastair K. Denniston, Krishnarajah Nirantharakumar, Nicola J. Adderley, PhD

Язык: Английский

---